AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27499030 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay of Events (DoE)
Number of subjects: 1079
Study 27499030 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Risk Reduction (RRR)
Number of subjects: 1079
Study 27499030 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute Risk Reduction (ARR)
Number of subjects: 1079
Study 26674353 — intervention group
Group type: EXPERIMENTAL
Intervention: Digene Hybrid Capture® 2 High‐Risk HPV DNA Test® (HC2)
Number of subjects: 6172
Study 26674353 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche cobas® 4800 HPV Test (COBAS)
Number of subjects: 6172
Study 26674353 — intervention group
Group type: COMPARATOR
Intervention: Liquid-based cytology (LBC)
Number of subjects: 6172
Study 26674353 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16
Number of subjects: 6172
Study 26674353 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 18
Number of subjects: 6172
Study 26674353 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade lesions
Number of subjects: 6172
Study 26674353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade lesions
Number of subjects: 6172
Study 26674353 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 and 18
Number of subjects: 6172
Study 22983689 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 12
Study 22983689 — intervention group
Group type: COMPARATOR
Intervention: Nasal dilator adhesive (NDA)
Number of subjects: 12
Study 22034850 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 week physical education (PE) intervention (2 hours per week of aerobically intense PE)
Number of subjects: 64
Study 22034850 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 week physical education (PE) intervention
Number of subjects: 64
Study 22034850 — intervention group
Group type: COMPARATOR
Intervention: Standard PE (control)
Number of subjects: 64
Study 18269981 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward QRS slope (I(US)) during PTCA
Number of subjects: 0
Study 18269981 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward QRS slope (I(DS)) during PTCA
Number of subjects: 0
Study 18269981 — intervention group
Group type: COMPARATOR
Intervention: High-frequency index (rms of bandpass-filtered QRS signal 150-250 Hz)
Number of subjects: 0
Study 18269981 — intervention group
Group type: COMPARATOR
Intervention: High-frequency index (optimum frequency band 125-175 Hz)
Number of subjects: 0
Study 17147870 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 22
Study 17147870 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 15206484 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (100 mg, twice a day)
Number of subjects: 283
Study 15206484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 11130524 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial endoscopy
Number of subjects: 422
Study 11130524 — intervention group
Group type: COMPARATOR
Intervention: Usual management (control)
Number of subjects: 422
Study 9360286 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate threat condition (feedback from a female partner)
Number of subjects: 70
Study 9360286 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat condition (feedback from a female partner)
Number of subjects: 70
Study 9360286 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral condition (feedback from a female partner)
Number of subjects: 70
Study 7903508 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 4
Study 7903508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐methyl‐para‐tyrosine and naloxone
Number of subjects: 4
Study 7903508 — intervention group
Group type: COMPARATOR
Intervention: Alpha‐methyl‐para‐tyrosine
Number of subjects: 4
Study 7903508 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study 3912112 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of cyclothiazide daily
Number of subjects: 12
Study 3912112 — intervention group
Group type: COMPARATOR
Intervention: 25 mg of hydrochlorthiazide daily
Number of subjects: 12
Study 3912112 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of cyclothiazide or hydrochlorthiazide
Number of subjects: 12
Study 30970404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized dust mite vaccine and conventional drugs
Number of subjects: 60
Study 30970404 — intervention group
Group type: COMPARATOR
Intervention: Placebo and conventional drugs (Control)
Number of subjects: 60
Study 30970404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 60
Study 30970404 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL4/IL10 ratio
Number of subjects: 60
Study 30239842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal testosterone (IVT) cream (300 μg per dose), self-administered daily for 2 weeks and then thrice weekly for 24 weeks
Number of subjects: 44
Study 30239842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal testosterone (IVT) cream
Number of subjects: 44
Study 30239842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27696203 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) 45 mg/m2 (days 6-8); 15 mg/m2 (days 9-21)
Number of subjects: 1100
Study 27696203 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive chemotherapy
Number of subjects: 1100
Study 25102884 — intervention group
Group type: EXPERIMENTAL
Intervention: DICLORAL
Number of subjects: 59
Study 25102884 — intervention group
Group type: COMPARATOR
Intervention: Compound Borax Solution
Number of subjects: 59
Study 21801115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of BoNT‐A (5 U) and BoNT‐B (500 U)
Number of subjects: 14
Study 21801115 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐A (10 U) alone
Number of subjects: 14
Study 19155235 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous cyclophosphamide (LD IVCY) followed by azathioprine (AZA)
Number of subjects: 90
Study 19155235 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous cyclophosphamide (HD IVCY) followed by azathioprine (AZA)
Number of subjects: 90
Study 18071724 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-Feverfew
Number of subjects: 0
Study 18071724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15699223 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie simple carbohydrate (HC-SC) meal
Number of subjects: 20
Study 15699223 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie complex carbohydrate (HC-CC) meal
Number of subjects: 20
Study 15699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie (LC) meal
Number of subjects: 20
Study 15699223 — intervention group
Group type: COMPARATOR
Intervention: All meals (HC-SC, HC-CC, LC)
Number of subjects: 20
Study 15699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective measures of hunger
Number of subjects: 20
Study 15699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 20
Study 15699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 20
Study 15699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 20
Study 15699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and Leptin
Number of subjects: 20
Study 12854476 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion at a rate of 0.01 microgram.kg‐1.min‐1 during and after the operation (60‐80 hrs)
Number of subjects: 20
Study 12854476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1 infusion)
Number of subjects: 20
Study 12854476 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion
Number of subjects: 20
Study 10596516 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention
Number of subjects: 25996
Study 10596516 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25996
Study 8605674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment during therapy
Number of subjects: 204
Study 8605674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment during follow-up
Number of subjects: 204
Study 8605674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment
Number of subjects: 204
Study 8605674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment at clinical progressive disease
Number of subjects: 204
Study 1974677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol aerosol 400 micrograms tid
Number of subjects: 38
Study 1974677 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol aerosol 200 micrograms tid
Number of subjects: 38
Study 526383 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with fentanyl plus atropine
Number of subjects: 74
Study 526383 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with diazepam plus atropine
Number of subjects: 74
Study 526383 — intervention group
Group type: COMPARATOR
Intervention: Etomidate anaesthesia without premedication
Number of subjects: 74
Study 31111049 — intervention group
Group type: EXPERIMENTAL
Intervention: HPVADL18® (200 mg Echinacea Purpurea and Echinacea Angustifolia) for 4 months after laser therapy
Number of subjects: 125
Study 31111049 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Control Group B)
Number of subjects: 125
Study 28218558 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different surgical procedures for primary palatal repair
Number of subjects: 448
Study 28218558 — intervention group
Group type: COMPARATOR
Intervention: Common procedure for primary palatal repair
Number of subjects: 448
Study 25415386 — intervention group
Group type: EXPERIMENTAL
Intervention: All-out pacing
Number of subjects: 15
Study 25415386 — intervention group
Group type: EXPERIMENTAL
Intervention: Athlete-controlled pacing
Number of subjects: 15
Study 25415386 — intervention group
Group type: COMPARATOR
Intervention: Computer-controlled pacing
Number of subjects: 15
Study 26120407 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 µgr every 6 hours until abortion or maximum 48 hours)
Number of subjects: 100
Study 26120407 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (50 units in 500 cc normal saline, increased to maximum 300 units) with laminaria (6 hours)
Number of subjects: 100
Study 26120407 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 100
Study 26120407 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 100
Study 21205237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (3-6 h after symptom onset)
Number of subjects: 2104
Study 21205237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (3-4.5 h after symptom onset)
Number of subjects: 2104
Study 21205237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (4.5-6 h after symptom onset)
Number of subjects: 2104
Study 21205237 — intervention group
Group type: COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator
Number of subjects: 2104
Study 20108853 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemius stretching for 3 weeks
Number of subjects: 16
Study 20108853 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 16
Study 16426264 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan (early administration)
Number of subjects: 20
Study 16426264 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan (late administration)
Number of subjects: 20
Study 15227617 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 221
Study 15227617 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine-proguanil
Number of subjects: 221
Study 11296099 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C‐CT) for 8 months (10 sessions)
Number of subjects: 156
Study 11296099 — intervention group
Group type: COMPARATOR
Intervention: Control (evaluation without CT)
Number of subjects: 156
Study 9247457 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 16
Study 8500499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyprogesterone caproate (OPC) administered preoperatively and after surgical and combined therapy for 6 to 36 months
Number of subjects: 540
Study 8500499 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Oxyprogesterone caproate (OPC) and Tamoxifen administered additionally to surgical and combined therapy
Number of subjects: 540
Study 8500499 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy in endometrial carcinoma patients
Number of subjects: 540
Study 3566252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone alone
Number of subjects: 0
Study 3566252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin alone
Number of subjects: 0
Study 3566252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone and tobramycin in combination
Number of subjects: 0
Study 31927126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 1378
Study 31927126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1378
Study 29914808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive supervised pelvic floor muscle training protocol (n=51)
Number of subjects: 99
Study 29914808 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n=48)
Number of subjects: 99
Study 27832671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic ‐ resistance training (CT)
Number of subjects: 32
Study 27832671 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 32
Study 24867893 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 30
Study 24867893 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 30
Study 22083332 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 120
Study 22083332 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 120
Study 20606239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rib raising
Number of subjects: 23
Study 20606239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (light touch)
Number of subjects: 23
Study 18253066 — intervention group
Group type: EXPERIMENTAL
Intervention: A. vera gel (97.5%)
Number of subjects: 40
Study 18253066 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone in placebo gel
Number of subjects: 40
Study 18253066 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 40
Study 18253066 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 40
Study 15986873 — intervention group
Group type: EXPERIMENTAL
Intervention: pegIFNalpha‐2a (180 microg/week) for 12 weeks
Number of subjects: 154
Study 15986873 — intervention group
Group type: EXPERIMENTAL
Intervention: pegIFNalpha‐2a (180 microg/week) plus ribavirin (800 mg/day)
Number of subjects: 154
Study 15986873 — intervention group
Group type: COMPARATOR
Intervention: pegIFNalpha‐2a (180 microg/week) plus placebo
Number of subjects: 154
Study 15986873 — intervention group
Group type: EXPERIMENTAL
Intervention: pegIFNalpha‐2a (180 microg/week)
Number of subjects: 154
Study 15986873 — intervention group
Group type: EXPERIMENTAL
Intervention: pegIFNalpha‐2a
Number of subjects: 154
Study 12643956 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention promoting self-regulatory practices
Number of subjects: 365
Study 12643956 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 365
Study 12643956 — intervention group
Group type: COMPARATOR
Intervention: Usual-eye-care control group
Number of subjects: 365
Study 10231302 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroscopy
Number of subjects: 102
Study 10231302 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 102
Study 10231302 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography
Number of subjects: 102
Study 8696717 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2, escalated by 250 mg/m2/week to 1750 mg/m2) and Cisplatin (25 mg/m2 escalated to 30 mg/m2) administered as 30 min infusions weekly x 3 with a week of rest.
Number of subjects: 32
Study 2062488 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 22
Study 2062488 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 22
Study 6133802 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine maleate/pseudoephedrine sulfate syrup
Number of subjects: 132
Study 6133802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 28008096 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry care umbilical cord method
Number of subjects: 8698
Study 28008096 — intervention group
Group type: COMPARATOR
Intervention: Antiseptic care
Number of subjects: 8698
Study 25498742 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage administered twice daily for 15 minutes
Number of subjects: 32
Study 25498742 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 32
Study 23323626 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic injection (bupivacaine) during banding
Number of subjects: 72
Study 23323626 — intervention group
Group type: COMPARATOR
Intervention: No local anaesthetic injection (control)
Number of subjects: 72
Study 20821330 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (400 mg/m2 bolus, 600 mg/m2 22 h continuous infusion day 1 and 2) + cisplatin (50 mg/m2 day 1) + pegylated liposomal doxorubicin (20 mg/m2 day 1 every two weeks)
Number of subjects: 78
Study 20821330 — intervention group
Group type: COMPARATOR
Intervention: 5-FU (400 mg/m2 bolus, 600 mg/m2 22 h continuous infusion day 1 and 2) + cisplatin (50 mg/m2 day 1) + mitomycin-C (7 mg/m2 every 6 weeks)
Number of subjects: 78
Study 20006142 — intervention group
Group type: EXPERIMENTAL
Intervention: A/Vietnam/1194/2004 A/H5N1 vaccine (5microg, 15microg or 45microg) with a 50microg LT adjuvant patch applied over the injection site
Number of subjects: 500
Study 20006142 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-injection/two-patch 45microg HA regimen
Number of subjects: 500
Study 20006142 — intervention group
Group type: EXPERIMENTAL
Intervention: A/Vietnam/1194/2004 A/H5N1 vaccine (45microg) with LT patch on second immunization
Number of subjects: 500
Study 20006142 — intervention group
Group type: COMPARATOR
Intervention: A/Vietnam/1194/2004 A/H5N1 vaccine (45microg) without LT patch
Number of subjects: 500
Study 15734614 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 342
Study 15734614 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 342
Study 12788477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin E
Number of subjects: 32
Study 12788477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10547405 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manual therapy
Number of subjects: 178
Study 10547405 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapies
Number of subjects: 178
Study 8690821 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of torsemide (75 mg over 24 hours with a 25 mg loading bolus)
Number of subjects: 0
Study 8690821 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus of torsemide (100 mg)
Number of subjects: 0
Study 2062989 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (6.13 mg)
Number of subjects: 30
Study 2062989 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (6.4 mg)
Number of subjects: 30
Study 2062989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Midazolam and Diazepam
Number of subjects: 30
Study 6342330 — intervention group
Group type: EXPERIMENTAL
Intervention: Moore hemiarthroplasty cemented with methyl methacrylate
Number of subjects: 29
Study 6342330 — intervention group
Group type: COMPARATOR
Intervention: Moore hemiarthroplasty noncemented prosthesis
Number of subjects: 29
Study 31996543 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (8 μg bolus)
Number of subjects: 102
Study 31996543 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (100 μg bolus)
Number of subjects: 102
Study 30866887 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check facilitated by trained lay advisors
Number of subjects: 246
Study 30866887 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 246
Study 30246750 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea mouthrinse
Number of subjects: 40
Study 30246750 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mouthrinse
Number of subjects: 40
Study 26826108 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration of proximal caries lesions
Number of subjects: 87
Study 26826108 — intervention group
Group type: COMPARATOR
Intervention: Individualized noninvasive measures alone (Control)
Number of subjects: 87
Study 24554246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 180
Study 24554246 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Trach Laryngeal Mask Airway (C-Trach)
Number of subjects: 180
Study 24554246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway (Cobra PLA)
Number of subjects: 180
Study 22294091 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive anterolateral approach (ALMI)
Number of subjects: 30
Study 22294091 — intervention group
Group type: COMPARATOR
Intervention: Modified direct-lateral approach (mDL)
Number of subjects: 30